drugset
Drugs / Foscarnet
last change Nov 2025 re-read 9 days ago

Foscarnet

also known as Foscarnet sodium · Foscavir · A-29622 · Dihydroxyphosphinecarboxylic acid oxide · EHB 776 · Foscarnet de sodio · Foscarnet sodique · Foscarnet sodium anhydrous · +6 more

Small molecule

Developed for
HIV infectious disease · cytomegalovirus retinitis · herpes simplex infectious disease · brain disorder · digestive system disorder · herpes zoster · radiculitis · cytomegalovirus infection
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Astra USA · Johns Hopkins University · Baylor College of Medicine · Icahn School of Medicine at Mount Sinai · Johns Hopkins Bloomberg School of Public Health
+18 more · Memorial Sloan Kettering Cancer Center · National Eye Institute (NEI) · New York Presbyterian Hospital · Northwestern University · University of California, Los Angeles · University of California, San Diego · University of California, San Francisco · University of Miami · University of Wisconsin, Madison · Cttq · Hoffmann-La Roche · Louisiana State University Health Sciences Center in New Orleans · NYU Langone Health · New York University · Peking University People's Hospital · Tulane University School of Medicine · University of Massachusetts, Worcester · University of North Carolina, Chapel Hill

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) FOSCAVIR — 1995-06-16 – 1997-01-24 fda.gov ↗
Approved US (FDA) FOSCAVIR — 1991-09-27 fda.gov ↗

Trials 22

today
US approved 1991
NCT02151240 · Ph 4 NCT00000766 · Ph 2 NCT00000970 · Ph 1 NCT00000134 · Ph 3 NCT00000691 · Ph 2 NCT00000729 · Ph 1 NCT00000665 · not/applicable NCT00000726 · Ph 1 NCT00001002 · Ph 1 NCT00000964 · Ph 1 NCT00000985 · Ph 3 NCT00000136 · Ph 3
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT00000729 ? → Jun 1992 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001002 ? → Jun 1991 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000964 ? → Oct 1990 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000726 ? → Feb 1992 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000856 — HIV infectious disease, brain disorder, radiculitis National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 1 NCT00000970 ? → Jun 1993 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00002144 — HIV infectious disease, herpes simplex infectious disease Astra USA Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00000697 — HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 2 NCT00000691 ? → Aug 1992 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00000766 ? → Sep 1995 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 34 trials
Phase 3 NCT00000134 Dec 1992 → Mar 1995 AIDS, cytomegalovirus retinitis Johns Hopkins Bloomberg School of Public Health Completed No outcome recorded
Phase 3 NCT00000136 Mar 1990 → Oct 1991 HIV infectious disease, cytomegalovirus retinitis Johns Hopkins Bloomberg School of Public Health Completed No outcome recorded
Phase 3 NCT00000985 ? → Oct 1990 HIV infectious disease, herpes simplex infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 3 NCT00002145 — HIV infectious disease, digestive system disorder Astra USA Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02151240 May 2014 → May 2015 herpes zoster Cttq Completed No outcome recorded
Phase 4 NCT00002125 — HIV infectious disease, cytomegalovirus retinitis Astra USA Completed No outcome recorded
Phase not applicable6 trials
— NCT00002039 — HIV infectious disease, cytomegalovirus retinitis Astra USA Completed No outcome recorded
— NCT00002021 — HIV infectious disease, herpes simplex infectious disease Astra USA Completed No outcome recorded
— NCT00002272 — HIV infectious disease, herpes simplex infectious disease Astra USA Completed No outcome recorded
— NCT00000665 ? → Apr 1992 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
— NCT00002301 — HIV infectious disease, cytomegalovirus retinitis Astra USA Unknown No outcome recorded
— NCT00002432 — HIV infectious disease, cytomegalovirus retinitis Astra USA Completed No outcome recorded
Comparator or background therapy8 trials
Phase 2 NCT01220895 Background Oct 2010 → Dec 2013 cytomegalovirus infection Cell Medica Ltd Completed No outcome recorded
Phase 2 NCT00986557 Background Sep 2009 → Aug 2013 graft versus host disease University Hospital Birmingham Unknown No outcome recorded
Phase 2 NCT00001061 Background ? → Mar 1998 HIV infectious disease, cytomegalovirus retinitis National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 3 NCT03073967 Comparator May 2017 → Aug 2025 herpes simplex infectious disease AiCuris Anti-infective Cures AG Completed Met primary
Phase 3 NCT02931539 Comparator Dec 2016 → Aug 2020 cytomegalovirus infection Shire Completed Met primary

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 31 sources stand behind the page.

FieldValueCited text
Known as Foscarnet “Foscarnet intermittent infusions of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours” NCT03073967 ↗
26

“Intravenous foscarnet 90 mg/kg twice daily” NCT01220895 ↗

“Intravenous foscarnet 90 mg/kg twice daily” NCT01077908 ↗

NCT00001002 ↗

NCT00002039 ↗

NCT00002272 ↗

NCT00002146 ↗

NCT00002145 ↗

NCT00000766 ↗

NCT00000856 ↗

NCT00000970 ↗

Show 16 more sources
Known as A-29622 ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Dihydroxyphosphinecarboxylic acid oxide ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as EHB 776 ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet de sodio ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet sodique ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet sodium “Treated With Foscavir (Foscarnet Sodium)” NCT00002125 ↗
4

“Foscarnet sodium” NCT00000970 ↗

NCT00001061 ↗

NCT02151240 ↗

NCT00986557 ↗
Known as Foscarnet sodium anhydrous ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet sodium hexahydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet sodium hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscarnet trisodium hexahydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as Foscavir “Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease” NCT00002145 ↗
1

“Treated With Foscavir (Foscarnet Sodium)” NCT00002125 ↗
Known as J05AD01 ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as NSC-313410 ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Known as NSC-758148 ChEMBL registry synonym — accepted as the source's own label CHEMBL666 ↗
Action Inhibit “by inhibiting the virus DNA polymerases” NCT00000726 ↗
Modality Small molecule — CHEMBL666 ↗
Route Intravenous “intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day” NCT00000134 ↗